Pola-R-ICE / GLA 2017-R2 (#1245)
Laufzeit: 01.01.2021 - 31.12.2040
Kurzfassung
An open-label, prospective phase III clinical study to compare Polatuzumab Vedotin plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) with Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
